GlassScriptPhysician profile
Steven L Carpenter
NPI 1952386898
$6,976.74
in general payments reported to CMS, 2019-2025
38 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $382 · 2021: $689 · 2022: $1,241 · 2023: $1,478 · 2024: $1,236 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,961.69 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $838.61 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $600.62 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $452.04 | 2019-2025 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $390.33 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $286.42 | 2019-2024 | |
| Boston Scientific Corporation | $201.06 | 2022-2024 | Exalt Model D |
| Ironwood Pharmaceuticals, INC | $199.61 | 2019-2025 | Linzess |
| Madrigal Pharmaceuticals | $179.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $169.18 | 2019-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $157.60 | 2024-2025 | Voquezna |
| Genzyme Corporation | $153.61 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $137.66 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $127.96 | 2020-2023 | |
| Celgene Corporation | $119.85 | 2021-2023 | Zeposia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $112.02 | 2025 | Esophyx |
| Medtronic, INC. | $90.90 | 2023 | Endoflip |
| Organon LLC | $87.07 | 2023-2024 | Hadlima, Renflexis |
| Medical Device Business Services, INC. | $86.67 | 2019 | |
| Intercept Pharmaceuticals, INC. | $86.07 | 2019-2025 | |
| Allergan, INC. | $69.54 | 2019-2020 | |
| Redhill Biopharma INC. | $56.16 | 2020-2022 | |
| Qol Medical, LLC | $53.96 | 2025 | Sucraid |
| Endogastric Solutions, INC | $49.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $43.58 | 2022 | |
| Enterra Medical, INC. | $40.20 | 2025 | |
| Alnylam Pharmaceuticals INC. | $30.95 | 2023 | Oxlumo, Givlaari |
| Shionogi INC | $24.09 | 2019 | |
| Janssen Scientific Affairs, LLC | $23.74 | 2019 | |
| Lilly USA, LLC | $22.65 | 2025 | Omvoh |
| Mylan Institutional INC. | $20.06 | 2023 | Hulio |
| Daiichi Sankyo INC. | $18.85 | 2019 | |
| Ucb, INC. | $17.33 | 2019 | |
| Braintree Laboratories, INC. | $15.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.54 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.75 | 2019 | |
| Amgen INC. | $13.20 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $11.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.